Table 4 Changes to treatment for opioid use disorder, telemedicine services, referral and release planning among EXIT-CJS community treatment program (CTP) sites (n = 7) during the post-COVID-19 period (April–September 2020)
| Â | Increased | No noticeable change | Decreased |
n (%) | |||
Treatment for opioid use disordera | |||
 Since COVID-19, have your clinical programs had any changes in the: | |||
  Number of persons admitted for OUD | 2 (33.3%) | 0 (0%) | 4 (66.7%) |
  Percent of persons admitted for OUD versus other disorders | 0 (0%) | 4 (66.7%) | 2 (33.3%) |
  Number of persons admitted needing opioid withdrawal management | 0 (0%) | 3 (60.0%) | 2 (40.0%) |
  Number of admitted persons self-reporting or screening positive for fentanyl/fentanyl analogues | 1 (2.0%) | 4 (80.0%) | 0 (0%) |
 Since COVID-19, has your program has any changes in the: | |||
  Number of providers waivered to prescribe buprenorphine | 1 (16.7%) | 5 (83.3%) | 0 (0%) |
  Demand for MOUD | 3 (50.0%) | 2 (33.3%) | 1 (16.7%) |
 Of those receiving MOUD for maintenance, how did the number of persons receiving methadone, buprenorphine, or naltrexone change in the months before and after COVID-19? | |||
  Methadoneb | 1 (25.0%) | 2 (50.0%) | 1 (25.0%) |
  Sublingual buprenorphineb | 1 (16.7%) | 3 (50.0%) | 2 (33.3%) |
  Extended-release buprenorphineb | 1 (16.7%) | 4 (66.7%) | 1 (16.7%) |
  Extended-release naltrexoneb | 0 (0%) | 5 (83.3%) | 1 (16.7%) |
 In the months before and after COVID-19, how did the number of CJS-involved persons being inducted onto MOUD in your facility/organization change? | |||
  Total number of persons inducted on MOUD | 1 (16.7%) | 4 (66.7%) | 1 (16.7%) |
  Number started for withdrawal management only | 0 (0%) | 6 (100%) | 0 (0%) |
  Number started for maintenance | 1 (16.7%) | 4 (66.7%) | 1 (16.7%) |
Changes to telemedicine use, n (%) | |||
| Â | Increased | No noticeable change | Decreased |
Since COVID-19, has your facility had any changes in use of telemedicine for:a | |||
 All health conditions | 6 (100%) | 0 (0%) | 0 (0%) |
 MOUD | 6 (100%) | 0 (0%) | 0 (0%) |
Since COVID-19, how has your facility/organization’s use of the following technology programs for substance use treatment or recovery support changed?b | |||
 Computers | 6 (100%) | 0 (0%) | 0 (0%) |
 Tablets | 5 (100%) | 0 (0%) | 0 (0%) |
 Kiosks | 1 (100%) | 0 (0%) | 0 (0%) |
 Cell phones | 5 (83.3%) | 1 (16.7%) | 0 (0%) |
 Internet | 3 (75.0%) | 1 (25.0%) | 0 (0%) |
 Text messaging | 4 (80.0%) | 1 (20.0%) | 0 (0%) |
 Email | 3 (75.0%) | 1 (25.0%) | 0 (0%) |
 Video calls | 6 (100%) | 0 (0%) | 0 (0%) |
 Other applications or software programs | 0 (0%) | 1 (100%) | 0 (0%) |
Changes to wraparound services and other supports, n (%) | |||
| Â | Increased | No noticeable change | Decreased |
Since COVID-19, how has your facility/organization’s provision of naloxone kits at release changed? | 3 (42.9%) | 4 (57.1%) | 0 (0%) |
How has COVID-19 impacted your facility/organization’s ability to provide:c | |||
 Housing assistance and homeless supports | 1 (16.7%) | 0 (0%) | 5 (83.3%) |
 Employment program and supports | 0 (0%) | 2 (33.3%) | 4 (66.7%) |
 Transportation support | 0 (0%) | 2 (33.3%) | 4 (66.7%) |